<DOC>
	<DOCNO>NCT00140686</DOCNO>
	<brief_summary>The main objective study determine vaccine efficacy rotavirus ( RV ) gastroenteritis ( GE ) first efficacy period .</brief_summary>
	<brief_title>To Test 2 Doses GSK Biologicals ' Oral Live Attenuated Human Rotavirus ( HRV ) Vaccine Healthy Infants Co-administration With Specific Childhood Vaccines</brief_title>
	<detailed_description>The study two group : Group HRV Group Placebo . Two oral dos administer healthy infant 6-14 week age time Dose 1 , accord 0 , 1 2-month schedule . Routine EPI vaccination give discretion investigator accord local National Plans Immunisation schedule participate country .</detailed_description>
	<mesh_term>Rotavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion : Healthy infant 6 14 week age time first study vaccination birth weight &gt; 2000g whose parent/guardian sign write informed consent whose parents/guardians comply requirement protocol ( e.g. , completion diary card , return followup visit ) . Exclusion criterion : Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Planned administration vaccine foreseen study protocol within 14 day dose study vaccine ( ) end 14 day . Chronic administration ( defined 14 day ) immunosuppressant since birth . ( Topical steroid allow . ) History diphtheria , tetanus , pertussis , Hib disease and/ hepatitis B disease ( subject ) . Only subject Spain : history meningococcal group C disease . Only subject France Germany : history disease cause Streptococcus pneumoniae . History use experimental rotavirus vaccine . Previous vaccination diphtheria , tetanus , pertussis , Haemophilus influenzae type b ( subject ) . Only subject Spain : previous vaccination meningococcal group C. Only subject France Germany : previous vaccination Streptococcus pneumoniae . Any clinically significant history chronic gastrointestinal disease include uncorrected congenital malformation GI tract , IS medical condition determine serious investigator . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination ( laboratory testing require ) . History allergic disease reaction likely exacerbated component vaccine . Acute disease time enrolment . ( Acute disease define presence moderate severe illness without fever . All vaccine administer person minor illness mild upper respiratory infection without lowgrade febrile illness , i.e . Oral temperature &lt; 37.5°C ( 99.5°F ) / Axillary temperature &lt; 37.5°C ( 99.5°F ) / Rectal temperature &lt; 38°C ( 100.4°F ) . ) Gastroenteritis within 7 day precede first study vaccine administration ( warrant deferral vaccination ) . A family history congenital hereditary immunodeficiency . Administration immunoglobulins and/or blood product since birth plan administration study period . History neurologic disorder seizure . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>14 Weeks</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>